Ovarian cancer is a deadly disease
and should be taken seriously. Early detection and monitoring of tumor
development is the key to survival. If someone gets tested regularly and
detects ovarian cancer early, their five-year survival rate can be as high as
93 percent, compared to a five-year survival rate of only 18 percent if
detected in the later stages. Avant Diagnostics, Inc. (OTCQB: AVDX) is a
medical diagnostic technology company that specializes in large panel biomarker
screening. The company’s first test, OvaDx, is a sophisticated microarray-based
test designed to detect pre-symptomatic ovarian cancer by measuring the
activation of the immune system in blood samples in response to early stage
ovarian tumor cell development.
According to the American Cancer
Society, more than 21,300 women were diagnosed with ovarian cancer last year,
ultimately leading to 14,200 deaths. With early detection, your chances
obviously improve, as mentioned above, so making the OvaDx test part of your
annual checkup should be a no-brainer. Considering the ramifications of just
going with the flow and cutting corners on regular monitoring of tumor
development during the treatment process, one would ascertain that constant
observation of which drugs are working and how well they are working would be
greatly beneficial to the patient.
The ovarian cancer diagnostic
market, where Avant Diagnostics competes, is worth more than $2 billion. With
innovative, necessary testing procedures like OvaDx, the company is positioned
to become a major game changer upon FDA approval. Some of the major players
engaged in personalized medicine and molecular diagnostics involving biomarkers
are global microarray market leader Affymetrix (NASDAQ: AFFX), which was
recently reported as having been acquired by competitor Thermo Fisher
Scientific (NYSE: TMO) for approximately $1.3 billion.
The standard approach to ovarian
cancer utilizes the combination of a platinum compound, such as Bristol-Myers
Squibb’s (NYSE: BMY) Platinol (cisplatin) or Paraplatin (carboplatin), and a
Taxane, such as Sanofi’s (NYSE: SNY) Taxotere (docetaxel) or Phyton Biotech’s
Taxol (paclitaxel). However, for patients with platinum-resistant/refractory
ovarian cancer, early detection is really the brass ring, even with such good
news out recently as Merck (NYSE: MRK) and Pfizer (NYSE: PFE) receiving FDA
approval for the first Phase III study of avelumab, an investigational, fully
human PD-L1 (programmed death-ligand 1) inhibitor that could emerge as a
treatment for platinum-resistant/refractory ovarian cancer.
For more information, visit the
company website at www.avantdiagnostics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment